KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Common Equity (2016 - 2025)

Gilead Sciences' Common Equity history spans 17 years, with the latest figure at $22.7 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 17.45% year-over-year to $22.7 billion; the TTM value through Dec 2025 reached $22.7 billion, up 17.45%, while the annual FY2025 figure was $22.7 billion, 17.45% up from the prior year.
  • Common Equity reached $22.7 billion in Q4 2025 per GILD's latest filing, up from $21.5 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $22.7 billion in Q4 2023 to a low of $17.5 billion in Q1 2024.
  • Average Common Equity over 5 years is $20.3 billion, with a median of $20.6 billion recorded in 2022.
  • Peak YoY movement for Common Equity: increased 22.9% in 2021, then dropped 17.32% in 2024.
  • A 5-year view of Common Equity shows it stood at $21.1 billion in 2021, then increased by 0.69% to $21.2 billion in 2022, then grew by 7.26% to $22.7 billion in 2023, then dropped by 15.03% to $19.3 billion in 2024, then increased by 17.45% to $22.7 billion in 2025.
  • Per Business Quant, the three most recent readings for GILD's Common Equity are $22.7 billion (Q4 2025), $21.5 billion (Q3 2025), and $19.6 billion (Q2 2025).